Related Experiment Videos
[Circulating cancer cells in the peripheral blood]
14th Department of Internal Medicine, Teikyo University, 3-8-3 Mizonokuchi, Takatsu-ku, Kawasaki 213-8507, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 4, 2001
Summary
Early detection of cancer cells in blood using molecular methods like RT-PCR shows promise for improved cancer staging and treatment monitoring. These advanced techniques offer higher sensitivity than older cytologic methods, potentially impacting clinical oncology practices.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Context:
- Cytologic methods for detecting circulating tumor cells (CTCs) have low sensitivity.
- Historical studies, like Engell's 1995 report, generated initial interest but were limited by technology.
- The advent of RT-PCR and other molecular techniques since 1987 revolutionized CTC detection.
Purpose:
- To evaluate the utility of molecular methods for identifying circulating cancer cells and micrometastases.
- To assess the correlation between CTC detection and patient outcomes in malignancies.
- To explore the potential impact of CTC detection on cancer staging and treatment monitoring.
Summary:
- Molecular methods, particularly RT-PCR, offer enhanced sensitivity for detecting circulating cancer cells (CTCs) and micrometastases in blood, bone marrow, and lymph nodes.
- Serial analyses by qualified laboratories have demonstrated a significant correlation between the presence of CTCs and cancer relapse in various malignancies.
- These findings suggest that CTC detection is a valuable tool for clinical decision-making.
Impact:
- Improved cancer staging through more accurate detection of disease spread.
- Enhanced monitoring of treatment effectiveness by tracking CTC levels.
- Potential to significantly alter clinical oncology practices by enabling earlier and more precise cancer management.